NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends

Jules Russick1, Carine Torset1, Edouard Hemery1

  • 1Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Team Inflammation, Complement and Cancer, F-75006, Paris, France.

Seminars in Immunology
|September 9, 2020
PubMed

Insights

Natural killer (NK) cells fight tumors but become exhausted within the tumor microenvironment. Strategies are being developed to overcome NK cell impairment and improve cancer immunotherapy.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Therapeutics

Background:

  • Natural killer (NK) cells are crucial for anti-tumor immunity and metastasis control within the tumor microenvironment.
  • NK cell infiltration into tumors is often limited, and tumor cells employ mechanisms to evade NK cell-mediated killing.
  • NK cells that do infiltrate tumors become functionally and metabolically impaired, impacting their prognostic and theranostic value.

Purpose of the Study:

  • To investigate the challenges of NK cell function in the tumor microenvironment.
  • To explore strategies for overcoming NK cell exhaustion and dysfunction.
  • To evaluate the potential of novel therapeutic tools for enhancing NK cell-based cancer immunotherapy.

Main Methods:

  • Review of current literature on NK cell biology in cancer.
  • Analysis of mechanisms of tumor immune evasion targeting NK cells.
  • Examination of emerging therapeutic strategies aimed at restoring NK cell function.

Main Results:

  • NK cell infiltration and function are significantly hampered in the tumor microenvironment.
  • Tumor cells develop diverse strategies to escape NK cell surveillance and attack.
  • NK cell impairment varies based on cancer type, stage, and microenvironment composition.
  • Therapeutic interventions show promise in revitalizing NK cell activity against tumors.

Conclusions:

  • NK cell dysfunction is a major hurdle in effective anti-tumor immunity.
  • Targeting NK cell exhaustion and improving tumor infiltration are critical for immunotherapy.
  • Developing and testing new therapeutic tools are essential for harnessing NK cell potential in cancer treatment.

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K